Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

124.96
+0.87040.70%
Post-market: 125.100.1395+0.11%19:30 EDT
Volume:13.89K
Turnover:1.74M
Market Cap:546.08M
PE:6.48
High:125.72
Open:125.36
Low:124.95
Close:124.09
52wk High:131.68
52wk Low:90.01
Shares:4.37M
Float Shares:4.37M
Volume Ratio:0.55
T/O Rate:0.32%
Dividend:1.06
Dividend Rate:0.85%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.75

Loading ...

Dow's 300-Point Drop Led by Losses in Shares of Nvidia Corp., Amgen

Dow Jones
·
Sep 10

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Sep 10

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Sep 10

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10

Sino Biopharmaceutical Stock Slides 2.3% in Hong Kong

Dow Jones
·
Sep 10

Amgen to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 10

Sweden's Biovica Q1 Sales Rise on Pharma Services Growth

Reuters
·
Sep 09

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Sep 09

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS
·
Sep 09

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS
·
Sep 09